Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Marinus Pharmaceuticals Inc
Pre-Tax Income
Marinus Pharmaceuticals Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
|
Pre-Tax Income
-$140.5m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-36%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Pre-Tax Income
$24.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pre-Tax Income
$9.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Pre-Tax Income
$7.5B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Pre-Tax Income
$21.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
29%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Pre-Tax Income
$25.7B
|
CAGR 3-Years
56%
|
CAGR 5-Years
29%
|
CAGR 10-Years
25%
|
|
Marinus Pharmaceuticals Inc
Glance View
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 113 full-time employees. The company went IPO on 2014-07-31. The firm is focused on the development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The Company’s lead product candidate is ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), which is developed for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). Ganaxolone is a methylated analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A (GABAA) receptors, a target known for its anti-seizure, antidepressant, and anxiolytic potential.
See Also
What is Marinus Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
-140.5m
USD
Based on the financial report for Sep 30, 2024, Marinus Pharmaceuticals Inc's Pre-Tax Income amounts to -140.5m USD.
What is Marinus Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-36%
Over the last year, the Pre-Tax Income growth was -5%. The average annual Pre-Tax Income growth rates for Marinus Pharmaceuticals Inc have been -17% over the past three years , -24% over the past five years , and -36% over the past ten years .
